Company Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States.

It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease.

The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio, Inc.

Country	United States
Founded	2017
IPO Date	Oct 9, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	Deborah Knobelman

Contact Details

Address: 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 United States
Phone	650 781 5200
Website	kronosbio.com

Stock Details

Ticker Symbol	KRON
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$19.00
CIK Code	0001741830
CUSIP Number	50107A104
ISIN Number	US50107A1043
SIC Code	2834

Key Executives

Name	Position
Dr. Deborah A. Knobelman Ph.D.	Interim Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and President
Joshua A. Kazam	Co-Founder and Director
David M. Tanen J.D.	Secretary and Director

Latest SEC Filings

Date	Type	Title
Apr 25, 2025	10-K/A	[Amend] Annual report
Apr 10, 2025	8-K	Current Report
Mar 18, 2025	10-K	Annual Report
Mar 18, 2025	8-K	Current Report
Dec 27, 2024	8-K	Current Report
Nov 27, 2024	8-K	Current Report
Nov 14, 2024	EFFECT	Notice of Effectiveness
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024	10-Q	Quarterly Report
Nov 13, 2024	8-K	Current Report

View All SEC Filings